Who owns AEGLEA BIOTHERAPEUTICS INC?
- Ticker: SYRE
- CUSIP Number: 00773j202
Tip: Access positions for across all investors
Analyze quarterly positions in Aeglea Biotherapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Aeglea Biotherapeutics stock
Who bought or sold AEGLEA BIOTHERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| FMR | 6.6M | $247M | 100% | Mar 2024 |
|
| Perceptive Advisors | 2.6M | $97M | -2% | Mar 2024 |
|
| VR Adviser | 2.2M | $82M | -8% | Mar 2024 |
|
| Commodore Capital | 1.9M | $72M | 0% | Mar 2024 |
|
| venBio Select Advisor | 1.8M | $40M | 15951% | Dec 2023 |
|
| Adage Capital Partners GP | 1.1M | $42M | 100% | Mar 2024 |
|
| Franklin Resources | 742k | $28M | 8% | Mar 2024 |
|
| Citadel Advisors | 708k | $27M | 23% | Mar 2024 |
|
| Wellington Management Company | 636k | $14M | 112% | Dec 2023 |
|
| BlackRock | 557k | $21M | 2716% | Mar 2024 |
|
| Braidwell | 515k | $20M | 0% | Mar 2024 |
|
| Vanguard Group | 497k | $19M | 1160% | Mar 2024 |
|
| Darwin Global Management | 473k | $18M | 100% | Mar 2024 |
|
| Farallon Capital Management | 466k | $18M | 100% | Mar 2024 |
|
| First Turn Management | 464k | $18M | 100% | Mar 2024 |
|
| Fairmount Funds Management | 378k | $14M | 0% | Mar 2024 |
|
| Geode Capital Management | 330k | $13M | 1132% | Mar 2024 |
|
| Millennium Management | 320k | $12M | 195% | Mar 2024 |
|
| Cormorant Asset Management | 250k | $9.5M | -73% | Mar 2024 |
|
| Boxer Capital | 250k | $9.5M | 0% | Mar 2024 |
|
| Logos Global Management | 250k | $9.5M | 67% | Mar 2024 |
|
| Goldman Sachs Group | 240k | $9.1M | 100% | Mar 2024 |
|
| Voloridge Investment Management | 188k | $7.1M | 100% | Mar 2024 |
|
| Suvretta Capital Management | 162k | $6.2M | 0% | Mar 2024 |
|
| Marshall Wace | 162k | $6.1M | 700% | Mar 2024 |
|
| HighVista Strategies | 154k | $5.9M | 100% | Mar 2024 |
|
| Dr. Jeffrey R. Jay, M.D. | 125k | $4.7M | 0% | Mar 2024 |
|
| Walleye Trading Advisors | 112k | $4.2M | 100% | Mar 2024 |
|
| Candriam Luxembourg S.C.A. | 105k | $4.0M | 100% | Mar 2024 |
|
| Susquehanna International | 102k | $3.9M | 100% | Mar 2024 |
|
| Woodline Partners | 101k | $3.8M | 100% | Mar 2024 |
|
| Integral Health Asset Management | 100k | $3.8M | 100% | Mar 2024 |
|
| Hrt Financial | 79k | $3.0M | 100% | Mar 2024 |
|
| T. Rowe Price Associates | 79k | $3.0M | 100% | Mar 2024 |
|
| Northern Trust | 66k | $2.5M | 100% | Mar 2024 |
|
| Assenagon Asset Management | 64k | $2.4M | 100% | Mar 2024 |
|
| TD Asset Management | 61k | $2.3M | 100% | Mar 2024 |
|
| Qube Research & Technologies | 58k | $2.2M | 100% | Mar 2024 |
|
| Morgan Stanley | 51k | $1.9M | 111178% | Mar 2024 |
|
| ADAR1 Capital Management | 50k | $1.9M | 669% | Mar 2024 |
|
| Cubist Systematic Strategies | 49k | $1.9M | 89% | Mar 2024 |
|
| Barclays | 46k | $1.7M | 1% | Mar 2024 |
|
| Swiss National Bank | 39k | $1.5M | 100% | Mar 2024 |
|
| Bank of America Corporation | 36k | $1.4M | 100% | Mar 2024 |
|
| Schonfeld Strategic Advisors | 36k | $1.3M | 100% | Mar 2024 |
|
| Balyasny Asset Management | 32k | $1.2M | 100% | Mar 2024 |
|
| Citigroup | 32k | $1.2M | 208% | Mar 2024 |
|
| Soros Fund Management | 30k | $1.1M | 100% | Mar 2024 |
|
| ExodusPoint Capital Management | 25k | $928k | 100% | Mar 2024 |
|
| Credit Suisse | 22k | $837k | 100% | Mar 2024 |
|
| Blackstone Group | 20k | $758k | 0% | Mar 2024 |
|
| Global Endowment Management | 18k | $690k | -96% | Mar 2024 |
|
| Fred Alger Management | 18k | $689k | 100% | Mar 2024 |
|
| Eudaimonia Asset Management | 18k | $680k | 100% | Mar 2024 |
|
| California State Teachers Retirement System | 18k | $675k | 100% | Mar 2024 |
|
| Legal & General Group | 17k | $646k | 100% | Mar 2024 |
|
| Virtu Financial | 16k | $615k | 100% | Mar 2024 |
|
| Engineers Gate Manager | 16k | $594k | 100% | Mar 2024 |
|
| Charles Schwab Investment Management | 15k | $569k | 100% | Mar 2024 |
|
| New York State Common Retirement Fund | 15k | $556k | 3919% | Mar 2024 |
|
| State of Wisconsin Investment Board | 15k | $555k | 100% | Mar 2024 |
|
| Henderson Group | 14k | $530k | 100% | Mar 2024 |
|
| Two Sigma Investments | 13k | $507k | -52% | Mar 2024 |
|
| Scientech Research | 13k | $499k | 100% | Mar 2024 |
|
| Legato Capital Management | 12k | $435k | 100% | Mar 2024 |
|
| EFG Asset Management | 11k | $423k | 100% | Mar 2024 |
|
| LMR Partners | 11k | $421k | 100% | Mar 2024 |
|
| Polymer Capital Management | 11k | $399k | 100% | Mar 2024 |
|
| Carlyle | 9.6k | $365k | 0% | Mar 2024 |
|
| Squarepoint Ops | 8.2k | $310k | 100% | Mar 2024 |
|
| Susquehanna Fundamental Investments | 8.1k | $306k | 100% | Mar 2024 |
|
| Jane Street | 7.2k | $274k | 100% | Mar 2024 |
|
| Chartwell Investment Partners | 6.8k | $259k | 100% | Mar 2024 |
|
| Bank of New York Mellon | 6.1k | $230k | 100% | Mar 2024 |
|
| Virtus ETF Advisers | 5.8k | $221k | -6% | Mar 2024 |
|
| Arizona State Retirement System | 5.4k | $207k | 100% | Mar 2024 |
|
| Tower Research Capital | 3.8k | $145k | 807% | Mar 2024 |
|
| UBS Group | 2.6k | $99k | -30% | Mar 2024 |
|
| Wells Fargo & Company | 2.2k | $85k | 9648% | Mar 2024 |
|
| Deutsche Bank Aktiengesellschaft | 298.00 | $11k | 100% | Mar 2024 |
|
| IFP Advisors | 114.00 | $2.5k | 0% | Dec 2023 |
|
| Advisor Group Holdings | 83.00 | $3.1k | -71% | Mar 2024 |
|
| Royal Bank of Canada | 56.00 | $2.0k | 100% | Mar 2024 |
|
| Point72 | 22.00 | $847.000000 | 100% | Mar 2024 |
|
| Jpmorgan Chase & Co | 11.00 | $417.000100 | -73% | Mar 2024 |
|
| Pacific Capital Wealth Advisors | 8.00 | $303.000000 | 0% | Mar 2024 |
|
Who sold out of Aeglea Biotherapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| EcoR1 Capital | Dec 2023 | 887k | $19M |
| BVF | Dec 2023 | 687k | $15M |
| Rock Springs Capital Management | Sep 2023 | 137k | $1.7M |
| Aisling Capital Management | Sep 2023 | 68k | $829k |
| Acadian Asset Management | Sep 2023 | 12k | $145k |